Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.52 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30304653 | 1.00 | MEN1 (0.57) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL4780290 | 0.86 | MEN1 (0.50) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL4781931 | 0.86 | GAA (0.50) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL3083591 | 0.84 | SLC20A2 (0.54) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL3101140 | 0.84 | SLC20A2 (0.52) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL4781221 | 0.84 | KMT2A (0.55) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL4781851 | 0.82 | AXL (0.49) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL4725832 | 0.82 | LMNA (0.47) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL7592771 | 0.82 | MEN1 (0.74) | MEN1KMT2AGAALMNANPSR1 | |
| SCHEMBL3078414 | 0.81 | SLC40A1 (0.57) | MEN1KMT2AGAALMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248672-A1 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | ADIMABIO LLC (US) | 2023-08-10 | — | — | US | claimed |
| EP-4181908-A2 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | Adimabio LLC (US) | 2023-05-24 | — | — | EP | claimed |
| CN-115943138-A | Compositions comprising GARDOS channel antagonists and uses thereof | 阿迪玛生物有限责任公司 | 2023-04-07 | — | — | CN | claimed |
| WO-2022015893-A2 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | ADIMABIO LLC (US) | 2022-01-20 | — | — | WO | claimed |
| WO-2018162426-A1 | TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-09-13 | — | — | WO | claimed |
| US-20180136227-A1 | Treatment and Diagnosis of Hereditary Xerocytosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-05-17 | — | — | US | claimed |
| EP-3106155-A1 | TREATMENT AND DIAGNOSIS OF HEREDITARY XEROCYTOSIS | Universite d'Aix Marseille (FR) | 2016-12-21 | — | — | EP | claimed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | AKIRABIO, INC. (US) | 2025-01-02 | — | — | US | disclosed |
| CN-118354759-A | Compositions comprising 2' -deoxycytidine analogs and their use for treating sickle cell disease, thalassemia and cancer | 阿基拉比奥有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | AKIRABIO, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230123277-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA | AKIRABIO INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230122664-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | CUSTOMERS BANK | 2023-04-20 | — | — | US | disclosed |
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | ADIMABIO LLC | 2023-02-23 | — | — | US | disclosed |
| US-7119112-B2 | Sulfonamides as potassium channel blockers | ICAGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1534259-A4 | SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS | ICAGEN INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-20060094721-A9 | Sulfonamides as potassium channel blockers | ICAGEN, INC. (US) | 2006-05-04 | — | — | US | disclosed |
| EP-1534259-A2 | SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS | Icagen, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040106613-A1 | Sulfonamides as potassium channel blockers | ICAGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004016221-A2 | SULFONAMIDES AS POTASSIUM CHANNEL BLOCKERS | ICAGEN, INC (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122664-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | MEN1 3869/4885KMT2A 1199/4885GAA 100/4885 |
| US-11938143-B2 | Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers | TYMP, HBZ, CDA | MEN1 3908/4885KMT2A 1141/4885GAA 102/4885 |
| US-20060094721-A9 | Sulfonamides as potassium channel blockers | KCNJ2, KCNJ1, KCNJ11 | MEN1 2417/4885KMT2A 441/4885GAA 1191/4885 |
| US-20230248672-A1 | COMPOSITIONS COMPRISING GARDOS CHANNEL ANTAGONISTS AND THEIR USES | CACNA1G, CACNA1I, CACNG2 | MEN1 3865/4885KMT2A 1832/4885GAA 335/4885 |
| US-20250000887-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | MEN1 3869/4885KMT2A 1199/4885GAA 100/4885 |
| US-20040106613-A1 | Sulfonamides as potassium channel blockers | KCNJ2, KCNJ1, KCNJ11 | MEN1 2417/4885KMT2A 441/4885GAA 1191/4885 |
| US-20230055298-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS | TYMP, HBZ, HBB | MEN1 3869/4885KMT2A 1199/4885GAA 100/4885 |
| US-20230123277-A1 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA | HBB, HBZ, TYMP | MEN1 4512/4885KMT2A 1401/4885GAA 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.